Dollar edges higher ahead of Fed minutes; sterling gains after CPI increase
WAYNE, Pa. - Teleflex Incorporated (NYSE:TFX), a medical technology company with annual revenues of $3.04 billion, announced Tuesday that its Barrigel rectal spacer is now available in Japan following regulatory approval from the Japanese Pharmaceuticals and Medical Devices Agency.
The product, which creates space between the prostate and rectum during radiation therapy, has begun clinical use in Japan earlier this month after receiving insurance coverage acceptance and appropriate use criteria from Japanese academic societies. According to InvestingPro analysis, Teleflex maintains strong financial health with a "GOOD" overall rating, suggesting robust operational capability to support this expansion.
According to a company press release, Barrigel is the first hyaluronic acid-based rectal spacer approved in Japan. The device is designed to reduce radiation exposure to the rectum during prostate cancer treatment.
Clinical data cited by the company showed that 98 percent of patients treated with Barrigel achieved at least a 25 percent reduction in rectal radiation exposure, with an average reduction of 85 percent in rectal V54 Gy radiation.
"This launch supports our mission to offer the next-generation, NASHA rectal spacer that enables precise, symmetrical placement," said Liam Kelly, Chairman, President and CEO of Teleflex. The company’s solid financial position is reflected in its impressive 55.89% gross margin and healthy current ratio of 2.41, indicating strong liquidity to fund its growth initiatives.
The company noted that prostate cancer was the most common cancer among Japanese men in 2022, with 104,318 new cases representing 18 percent of all cancer diagnoses nationwide.
Physician training for the product began in late May in Chiba, Japan, under the direction of Dr. Jun Itami, a prominent radiation oncologist in the country.
The Barrigel rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA), a substance naturally present in the human body that is biocompatible and fully absorbable. The product has previously received clearance in the United States, Australia, and Europe. InvestingPro data suggests Teleflex is currently undervalued, with additional financial insights and detailed analysis available in the Pro Research Report, covering this and 1,400+ other top US stocks.
In other recent news, Teleflex Incorporated reported strong second-quarter 2025 earnings, with both earnings per share (EPS) and revenue exceeding expectations. The company’s EPS was $3.73, surpassing the forecasted $3.36, representing an 11.01% surprise. Revenue reached $780.9 million, slightly above the anticipated $771.52 million. Following these results, RBC Capital raised its price target for Teleflex to $135 from $130, maintaining a Sector Perform rating. The positive earnings report was attributed to operational improvements, and the company also increased its 2025 mid-point EPS guidance by 5%. These developments indicate a robust performance for Teleflex in the recent quarter, drawing attention from analysts and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.